Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 29;25(1):2570.
doi: 10.1186/s12889-025-23791-0.

High-risk human papillomavirus testing for underscreened populations: cost-effectiveness and affordability in three country settings

Marat Sultanov  1 , Geertruida H de Bock  2 , Jaap A R Koot  3 , Janine de Zeeuw  3 , Marcel J W Greuter  4 , Fengming Pan  2 , Jelle Stekelenburg  3   5 , Jogchum J Beltman  6 , Marlieke de Fouw  6 , Carolyn Nakisige  7 , Johnblack K Kabukye  7   8 , Ezra Anecho  7 , Naheed Nazrul  9 , Mosamat U Kulsum  9 , Aminur Rahman  10 , Marek Majdan  11 , Juliana Melichová  11 , Jaroslava Sokolová  12 , Jurjen van der Schans  3   13
Affiliations

High-risk human papillomavirus testing for underscreened populations: cost-effectiveness and affordability in three country settings

Marat Sultanov et al. BMC Public Health. .

Abstract

Background: The high-risk human papillomavirus (hrHPV)-based screening recommended by the World Health Organization is expected to lead to worldwide reduction of the cervical cancer burden, but the countries burdened most by cervical cancer also struggle with the costs of transitioning to this approach. Country-specific evaluations are needed to inform policymakers on implementation of hrHPV-based screening for their setting. Following initial implementation in Uganda, Bangladesh and Slovakia focused on underscreened women in the PRESCRIP-TEC project, we investigated the potential cost-effectiveness and affordability of hrHPV-based screening strategies.

Methods: Country-specific model-based cost-effectiveness and budget impact analyses were conducted for the three countries, comparing the PRESCRIP-TEC strategy with the existing screening strategy in each setting. Data from initial project implementation informed the relevant model parameters.

Results: The PRESCRIP-TEC strategy resulted in disability-adjusted life year (DALY) gains in all three countries. The cervical cancer incidence rate was reduced by a third for Uganda, 15% for Bangladesh and 11% for Slovakia. The incremental cost-effectiveness ratios were UGX 0.56 million per DALY for Uganda (I$ 475), BDT 76 thousand per DALY for Bangladesh (I$ 1698) and EUR 1782 (I$ 3637) per DALY for Slovakia. Substantial additional funding will be required to enable implementation, particularly in relation to the initial start-up costs.

Conclusions: The provided estimates can serve to inform policymakers and researchers in the context of implementing hrHPV-based screening in diverse settings.

Keywords: Budget impact; Cervical cancer; Cost-effectiveness; Economic evaluation; High-risk human papillomavirus; Screening.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Disease model structure. The 1-year transition probabilities between health states are represented by arrows from states (placed above the state) and to states (placed below the state). HrHPV - high-risk human papillomavirus, CIN - cervical intraepithelial neoplasia
Fig. 2
Fig. 2
Cost-effectiveness acceptability curve - Uganda. The plotted curve represents the proportion of simulations with positive incremental DALYs and costs under each WTP threshold level (expressed as proportions of GDP per capita in 10% increments). WTP - willingness-to-pay, GDP - gross domestic product
Fig. 3
Fig. 3
Cost-effectiveness acceptability curve - Bangladesh. The plotted curve represents the proportion of simulations with positive incremental DALYs and costs under each WTP threshold level (expressed as proportions of GDP per capita in 10% increments). WTP - willingness-to-pay, GDP - gross domestic product
Fig. 4
Fig. 4
Cost-effectiveness acceptability curve – Slovak Republic. The plotted curve represents the proportion of simulations with positive incremental DALYs and costs under each WTP threshold level (expressed as proportions of GDP per capita in 10% increments). WTP - willingness-to-pay, GDP - gross domestic product
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. - PubMed
    1. Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10:e1115–27. - PMC - PubMed
    1. Allanson E, Schmeler K. Cervical cancer prevention in low and middle income countries. Clin Obstet Gynecol. 2021;64:501–18. - PMC - PubMed
    1. Mallafré-Larrosa M, Ritchie D, Papi G, Mosquera I, Mensah K, Lucas E, et al. Survey of current policies towards widening cervical screening coverage among vulnerable women in 22 European countries. Eur J Public Health. 2023;33:502–8. - PMC - PubMed
    1. Descamps P, Dixon S, Bosch Jose FX, Kyrgiou M, Monsonego J, Neisingh O, et al. Turning the tide—Recommendations to increase cervical cancer screening among women who are underscreened. Int J Gynecol Obstet. 2024;166:3–21. - PubMed

MeSH terms